Switch theme
Sign up to access all valuation multiples
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
2021
50
Last FY Revenue n/a
LTM EBITDA -$53.3M
$454M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
GH Research has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$53.3M.
In the most recent fiscal year, GH Research achieved revenue of n/a and an EBITDA of -$38.6M.
GH Research expects next 12-month revenue of XXX and NTM EBITDA of XXX
See GH Research valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$53.3M | XXX | -$38.6M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$54.9M | XXX | -$50.2M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$46.7M | XXX | -$39.0M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, GH Research's stock price is $12.
GH Research has current market cap of $744M, and EV of $454M.
See GH Research trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $454M | $744M | XXX | XXX | XXX | XXX | $-0.83 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, GH Research has market cap of $744M and EV of $454M.
GH Research's trades at n/a EV/Revenue multiple, and -11.8x EV/EBITDA.
Equity research analysts estimate GH Research's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
GH Research has a P/E ratio of -15.9x.
See valuation multiples for GH Research and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $744M | XXX | $744M | XXX | XXX | XXX |
| EV (current) | $454M | XXX | $454M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -8.5x | XXX | -11.8x | XXX | XXX | XXX |
| EV/EBIT | -8.3x | XXX | -9.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -15.9x | XXX | -19.1x | XXX | XXX | XXX |
| EV/FCF | -10.4x | XXX | -10.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGH Research's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.0M for the same period.
GH Research's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
GH Research's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for GH Research and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 33% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
GH Research acquired XXX companies to date.
Last acquisition by GH Research was XXXXXXXX, XXXXX XXXXX XXXXXX . GH Research acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was GH Research founded? | GH Research was founded in 2021. |
| Where is GH Research headquartered? | GH Research is headquartered in United States of America. |
| How many employees does GH Research have? | As of today, GH Research has 50 employees. |
| Who is the CEO of GH Research? | GH Research's CEO is Dr. Velichka Valcheva, M.D.,M.Sc.. |
| Is GH Research publicy listed? | Yes, GH Research is a public company listed on NAS. |
| What is the stock symbol of GH Research? | GH Research trades under GHRS ticker. |
| When did GH Research go public? | GH Research went public in 2021. |
| Who are competitors of GH Research? | Similar companies to GH Research include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of GH Research? | GH Research's current market cap is $744M |
| Is GH Research profitable? | Yes, GH Research is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of GH Research? | GH Research's last 12 months EBITDA is -$53.3M. |
| What is the current EV/EBITDA multiple of GH Research? | Current EBITDA multiple of GH Research is -8.5x. |
| What is the current FCF of GH Research? | GH Research's last 12 months FCF is -$43.6M. |
| What is the current EV/FCF multiple of GH Research? | Current FCF multiple of GH Research is -10.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
